TRIM25 Promotes Hepatocellular Carcinoma Bone Metastasis by Stabilizing SMAD3-VDR Complex via SMURF2 Degradation

Authors:
  • RDRuipeng Dong
    Ruipeng Dong
  • LYLiming Yao
    Liming Yao
  • NMNanfeng Meng
    Nanfeng Meng
  • LLLuan Li
    Luan Li
  • YSYanlai Sun
    Yanlai Sun
  • KLKaiming Leng
    Kaiming Leng
  • GSGuangjun Shi
    Guangjun Shi

Abstract
Bone metastasis is a lethal complication of hepatocellular carcinoma (HCC) characterized by severe osteolytic lesions, yet the underlying mechanisms driving osteoclast hyperactivation remain poorly understood. Using quantitative proteomic profiling of clinical cohorts, we identified the E3 ubiquitin ligase TRIM25 as being significantly upregulated specifically in HCC patients with bone metastasis. Elevated TRIM25 expression strongly correlates with poor clinical outcomes, serving as a powerful prognostic indicator. In vivo and in vitro models demonstrated that TRIM25 overexpression significantly accelerates bone colonization and exacerbates osteolytic bone destruction. This aggressive phenotype is driven by the massive paracrine secretion of RANKL from HCC, which profoundly hyperactivates osteoclastogenesis. Mechanistically, we elucidated a dual-ubiquitination regulatory cascade: TRIM25 directly binds to another E3 ligase, SMURF2, catalyzing its K48-linked poly-ubiquitination and subsequent proteasomal degradation. The destruction of SMURF2 acts as an upstream de-repressor that stabilizes SMAD3, facilitating its functional assembly with the Vitamin D Receptor (VDR). This stabilized SMAD3-VDR complex then synergistically transactivates the RANKL promoter, driving robust RANKL expression independent of the canonical TGF-β pathway. Collectively, our study uncovers a previously unrecognized TRIM25-SMURF2-SMAD3/VDR-RANKL signaling axis that orchestrates the tumor-bone microenvironment. Targeting this ubiquitination-driven cascade represents a promising therapeutic strategy to disrupt the vicious cycle of osteolytic bone metastasis in HCC.